{"id":1081699,"date":"2026-09-24T05:08:29","date_gmt":"2026-09-24T05:08:29","guid":{"rendered":"https:\/\/www.europesays.com\/us\/1081699\/"},"modified":"2026-09-24T05:08:29","modified_gmt":"2026-09-24T05:08:29","slug":"thyroid-medication-recall-vitruvias-therapeutics-inc","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/1081699\/","title":{"rendered":"Thyroid medication recall: Vitruvias Therapeutics Inc."},"content":{"rendered":"<p>(<a href=\"https:\/\/fox8.com\/news\/thyroid-medication-recall-classified-as-fdas-most-urgent\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">WJW<\/a>) \u2013 A nationwide <a href=\"https:\/\/fox8.com\/news\/thyroid-tablets-could-be-superpotent-warns-fda-in-urgent-recall-alert\/\" data-type=\"link\" data-id=\"https:\/\/fox8.com\/news\/thyroid-tablets-could-be-superpotent-warns-fda-in-urgent-recall-alert\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">recall on thyroid tablets<\/a> has now been classified as one the U.S. Food and Drug Administration\u2019s most serious and urgent recalls.<\/p>\n<p>According to the <a href=\"https:\/\/www.fda.gov\/safety\/recalls-market-withdrawals-safety-alerts\/vitruvias-therapeutics-inc-issues-nationwide-recall-one-lot-thyroid-tablets-usp-30-mg-due-potential\" data-type=\"link\" data-id=\"https:\/\/www.fda.gov\/safety\/recalls-market-withdrawals-safety-alerts\/vitruvias-therapeutics-inc-issues-nationwide-recall-one-lot-thyroid-tablets-usp-30-mg-due-potential\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">recall alert<\/a>, which was first announced in August, there were concerns that the medication could be overly potent and potentially cause symptoms related to an overactive thyroid.<\/p>\n<p>\t<a href=\"https:\/\/pix11.com\/\" class=\"promo-link__link\" target=\"&quot;_blank&quot;\" rel=\"nofollow noopener\"><br \/>\n\t\tDiscover more local reporting on our homepage\t<\/a><\/p>\n<p>On Wednesday, the FDA <a href=\"https:\/\/www.accessdata.fda.gov\/scripts\/ires\/index.cfm\" data-type=\"link\" data-id=\"https:\/\/www.accessdata.fda.gov\/scripts\/ires\/index.cfm\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">updated the recall<\/a>, listing it as <a href=\"https:\/\/www.fda.gov\/safety\/industry-guidance-recalls\/recalls-background-and-definitions\" data-type=\"link\" data-id=\"https:\/\/www.fda.gov\/safety\/industry-guidance-recalls\/recalls-background-and-definitions\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">Class I<\/a>, which is defined as a situation in which there is a \u201creasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death.\u201d<\/p>\n<p>In August, Vitruvias Therapeutics Inc. voluntarily recalled one lot of its Thyroid Tablets after testing confirmed the potential for the product to be \u201c<a href=\"https:\/\/www.fda.gov\/safety\/recalls-market-withdrawals-safety-alerts\/vitruvias-therapeutics-inc-issues-nationwide-recall-one-lot-thyroid-tablets-usp-30-mg-due-potential\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">superpotent<\/a>.\u201d<\/p>\n<p><a href=\"https:\/\/fox8.com\/wp-content\/uploads\/sites\/12\/2026\/08\/Thyroid-Tablet-recall_FDA.png\" rel=\"nofollow noopener\" target=\"_blank\"><img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.europesays.com\/us\/wp-content\/uploads\/2026\/09\/Thyroid-Tablet-recall_FDA.png\" alt=\"\" class=\"wp-image-3761313\"  \/><\/a><\/p>\n<p>The statement warned that superpotent Thyroid tablets can cause hyperthyroidism (overactive thyroid) including symptoms such as weight loss, heat intolerance, fatigue, nervousness, muscle weakness, hypertension, chest pain, rapid heart rate, or heart rhythm disturbances.<\/p>\n<p>Elderly people, pregnant women, and infants, are at greater risk of adverse effects, especially over extended periods of time, warned the <a href=\"https:\/\/www.fda.gov\/safety\/recalls-market-withdrawals-safety-alerts\/vitruvias-therapeutics-inc-issues-nationwide-recall-one-lot-thyroid-tablets-usp-30-mg-due-potential\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">recall<\/a>.<\/p>\n<p>Here\u2019s what to check for:<\/p>\n<tr><strong>Product<\/strong><strong>NDC<\/strong><strong>Lot<\/strong><strong>Exp Date<\/strong><strong>Units\u00a0<\/strong><br \/><strong>Released<\/strong><strong>Units\u00a0<\/strong><br \/><strong>Sold<\/strong><strong>First\u00a0<\/strong><br \/><strong>Distribution\u00a0<\/strong><br \/><strong>Date<\/strong><strong>Last\u00a0<\/strong><br \/><strong>Distribution\u00a0<\/strong><br \/><strong>Date<\/strong><\/tr>\n<tr>\n<td>Thyroid\u00a0<br \/>Tablets,\u00a0<br \/>USP 30 mg<\/td>\n<td>69680-\u00a0<br \/>166-00<\/td>\n<td>504950<\/td>\n<td>9\/30\/2026<\/td>\n<td>3,655<\/td>\n<td>1,955<\/td>\n<td>1\/31\/2025<\/td>\n<td>9\/30\/2025<\/td>\n<\/tr>\n<p>At the time of the <a href=\"https:\/\/www.fda.gov\/safety\/recalls-market-withdrawals-safety-alerts\/vitruvias-therapeutics-inc-issues-nationwide-recall-one-lot-thyroid-tablets-usp-30-mg-due-potential\" data-type=\"link\" data-id=\"https:\/\/www.fda.gov\/safety\/recalls-market-withdrawals-safety-alerts\/vitruvias-therapeutics-inc-issues-nationwide-recall-one-lot-thyroid-tablets-usp-30-mg-due-potential\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">initial recall<\/a>, patients were advised that they shouldn\u2019t stop using the medication without contacting their health care provider for further guidance or a replacement prescription. <\/p>\n<p>Consumers with questions about the recall can contact Vitruvias Therapeutics, Inc. by email at <a href=\"https:\/\/pix11.com\/news\/us-world-news\/thyroid-medication-recall-classified-under-fdas-most-urgent-level\/mailto:safety@vitruvias.com\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">safety@vitruvias.com<\/a> or by phone at (256) 239-9373 Monday through Friday from 9 a.m. to 5 p.m. CT.<\/p>\n<p>Consumers should contact their physician or health care provider if they have experienced any problems that may be related to taking the medication.<\/p>\n","protected":false},"excerpt":{"rendered":"(WJW) \u2013 A nationwide recall on thyroid tablets has now been classified as one the U.S. Food and&hellip;\n","protected":false},"author":3,"featured_media":1081700,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[34],"tags":[210,1060,44400,67,132,68],"class_list":["post-1081699","post","type-post","status-publish","format-standard","has-post-thumbnail","category-medication","tag-health","tag-medication","tag-nmw","tag-united-states","tag-unitedstates","tag-us"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/117324292920762578","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/1081699","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=1081699"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/1081699\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/1081700"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=1081699"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=1081699"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=1081699"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}